A First-in-Human Single and Multiple Ascending Dose Study of MT-201

Part of paid clinical trials in San Diego, California.

Sponsor
Mirador Therapeutics, Inc.
Study ID
NCT07219368
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MT-201 — DRUG
    MT-201
  • Placebo — DRUG
    Placebo

Study Details

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

Key Dates

Start date
Oct 8, 2025
Status verified
Oct 2025
Primary completion
Nov 24, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
72 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Single Ascending Dose of MT-201
    To assess the safety and tolerability of single intravenous/subcutaneous doses of MT-201
  • Experimental: Multiple Ascending Dose of MT-201
    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of MT-201
  • Placebo Comparator: Single Ascending Dose Placebo Arm
    To assess the safety and tolerability of single intravenous/subcutaneous doses of placebo
  • Placebo Comparator: Multiple Ascending Dose Placebo
    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of placebo

Primary Outcome Measure

Number of Participants with non-SAEs and SAES [ Time Frame: Up to 40 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mirador Clinical Department, San Diego, California 92121San DiegoCalifornia92121
Mirador Clinical Department
[email protected]
844-206-4980
Toll-Free Number

Find similar trials in San Diego, CA

By research site
Mirador Clinical Department, San Diego, California 92121· San Diego, CA

Related Studies